Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01

Veradermics Incorporated (NYSE:MANE) is one of the small-cap stocks that are on fire right now. On April 27, Veradermics announced positive topline results from its Phase 2/3 “302” clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation for male pattern hair loss. The study, which included 519 participants, met all primary and key secondary endpoints with high statistical significance.

The trial also highlighted strong patient and investigator satisfaction. ~80% to 86% of patients reported improvements in hair coverage. This consistent response across the study population suggests that VDPHL01 could offer a highly reliable and differentiated clinical profile compared to existing off-label or over-the-counter options. Safety data for VDPHL01 was equally encouraging, demonstrating a favorable tolerability profile with adverse event rates similar to those of the placebo.

Andrey_Popov/Shutterstock.com

The extended-release gel matrix is specifically designed to maintain steady absorption while avoiding the high peak concentrations often linked to cardiac side effects. If approved, VDPHL01 would become the first non-hormonal oral treatment for pattern hair loss cleared by the FDA in nearly 30 years, potentially addressing a significant unmet need for the 80 million men and women in the U.S. currently suffering from the condition.

Veradermics Incorporated (NYSE:MANE) develops therapies for dermatologic and aesthetic conditions.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.